Fig. 3: Expression of oncogenes and replication stress markers in breast cancer.

a Analysis of staining intensities of replication stress markers, γ-H2AX and pRPA32 (Ser33) in breast cancer TMAs (n = 384). (b) Patients from the combined cohort (n = 384) and breast cancer subgroups ER/PR⁺HER2⁻ (n = 161), ER/PR⁺HER2⁺ (n = 90), ER/PR⁻HER2⁺ (n = 27) and ER/PR⁻HER2⁻ (n = 106) were analyzed. Tumor tissue was immunohistochemically scored for expression of oncogenes (Cyclin E (n), Cyclin E (c), c-Myc, Cdc25A), indicated P values were calculated using Mann–Whitney U test. Box plots represent medians and interquartile range. Whiskers represent 10th and 90th percentile. c TNBC patients (ER/PR⁻HER2⁻, n = 106) were compared with non-TNBC breast cancers (n = 278) for expression of replication stress markers pRPA and γ-H2AX. Box plots represent medians and interquartile range. Whiskers represent 10th and 90th percentile. d Tumor tissue from the combined cohort (n = 384) was immunohistochemically scored for expression of oncogenes (Cyclin E (n), Cyclin E (c), Cdc25A and c-Myc). Cyclin E scores were classified into nuclear and cytoplasm negative (N−/C−, n = 113), nuclear positive and cytoplasm negative (N+/C−, n = 78) and either nuclear positive or negative and cytoplasm positive (C+, n = 193). An additional subclassification was performed based on breast cancer subgroups ER/PR⁺HER2⁻, ER/PR⁺HER2⁺, ER/PR⁻HER2⁺ and TNBC. For all subgroups or the total cohort, tumor expression of replication stress markers (pRPA and γ-H2AX) was assessed, indicated P values were calculated using Mann–Whitney U test. “Ns” indicates not significant. * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, **** indicates P < 0.0001. Medians and standard deviations are indicated.